13402 related articles for article (PubMed ID: 10219884)
1. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
2. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
4. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
Colao A; Ferone D; Lombardi G; Lastoria S
Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
[TBL] [Abstract][Full Text] [Related]
5. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
6. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
7. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
[TBL] [Abstract][Full Text] [Related]
8. 111In-octreotide scintigraphy in pituitary adenomas.
Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor imaging in intracranial tumours.
Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
[TBL] [Abstract][Full Text] [Related]
10. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy.
Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M
J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670
[TBL] [Abstract][Full Text] [Related]
11. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
[TBL] [Abstract][Full Text] [Related]
12. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
Colao A; Merola B; Ferone D; Marzullo P; Cerbone G; Longobardi S; Di Somma C; Lombardi G
Eur J Endocrinol; 1995 Aug; 133(2):189-94. PubMed ID: 7655643
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
14. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands.
van Royen EA; Verhoeff NP; Meylaerts SA; Miedema AR
J Nucl Med; 1996 Sep; 37(9):1449-51. PubMed ID: 8790190
[TBL] [Abstract][Full Text] [Related]
15. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
[TBL] [Abstract][Full Text] [Related]
17. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
Lundin P; Edén Engström B; Karlsson FA; Burman P
AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
[TBL] [Abstract][Full Text] [Related]
18. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
[TBL] [Abstract][Full Text] [Related]
19. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
20. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
